Key Points
- Insider sale: Director Suma Krishnan sold 25,000 shares on March 4 at an average price of $263.21 for a $6.58 million transaction, reducing her stake by 1.75% to 1,403,155 shares.
- Earnings and analyst sentiment: Krystal beat Q4 estimates with $1.70 EPS (vs. $1.62) and $107.11M revenue, shows strong profitability (52.64% net margin), and carries a consensus "Moderate Buy" rating with a $326.25 target.
- Business focus: Krystal is a clinical-stage gene therapy company targeting rare dermatological diseases, with lead candidate KB103 for dystrophic epidermolysis bullosa (DEB).
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the sale, the insider owned 1,403,155 shares in the company, valued at $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Krystal Biotech Trading Down 2.6%
KRYS opened at $253.69 on Friday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $298.30. The company has a market cap of $7.42 billion, a PE ratio of 37.04 and a beta of 0.49. The company has a 50 day moving average of $269.86 and a 200 day moving average of $218.28.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analysts' expectations of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Weiss Ratings upgraded Krystal Biotech from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, February 18th. Bank of America raised their target price on Krystal Biotech from $288.00 to $318.00 and gave the stock a "buy" rating in a research note on Thursday, January 22nd. Zacks Research lowered Krystal Biotech from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 5th. Chardan Capital upped their price target on Krystal Biotech from $220.00 to $323.00 and gave the company a "buy" rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group increased their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $326.25.
Get Our Latest Stock Report on KRYS
Institutional Investors Weigh In On Krystal Biotech
A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. UMB Bank n.a. boosted its stake in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock valued at $36,000 after buying an additional 37 shares during the period. Optimize Financial Inc increased its stake in Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company's stock worth $704,000 after acquiring an additional 40 shares during the last quarter. Perigon Wealth Management LLC increased its stake in Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company's stock worth $2,211,000 after acquiring an additional 41 shares during the last quarter. Regal Investment Advisors LLC raised its holdings in shares of Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company's stock valued at $1,075,000 after acquiring an additional 44 shares in the last quarter. Finally, Crossmark Global Holdings Inc. raised its holdings in shares of Krystal Biotech by 2.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company's stock valued at $524,000 after acquiring an additional 55 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
